Lung Stents Market - Global Forecast 2025-2032

The lung stents market is evolving rapidly in response to major advances in respiratory care, shifting clinical needs, and changing global regulatory and trade frameworks. Senior leaders require a clear view of industry shifts, emerging opportunities, and risks to drive strategic decisions in this dynamic sector.

Market Snapshot: Lung Stents Market Outlook

The Lung Stents Market grew from USD 124.09 million in 2024 to USD 134.35 million in 2025. It is expected to continue growing at a CAGR of 8.32%, reaching USD 235.23 million by 2032. Demand drivers include advancements in minimally invasive therapies, increased adoption by hospitals and clinics, and the expanding application for airway management across multiple patient groups. Product innovation and ongoing regulatory reforms contribute to sustained growth and diversification globally.

Scope & Segmentation of the Global Lung Stents Market

• Product Types: Bioresorbable stents (Magnesium-Based, PLLA-Based), Drug-Eluting Stents, Metallic Stents, Polymer Stents (Biodegradable, Nondegradable)
• Indications: Airway Obstruction, Malacia, Tracheobronchial Stenosis, Tumor (Benign Tumor, Malignant Tumor)
• Material Types: Nitinol, Polymer-Based (Poly-L-Lactic Acid, Polycarbonate Urethane), Stainless Steel
• Patient Age Groups: Adult, Geriatric, Pediatric
• Distribution Channels: Ambulatory Surgical Centers, Clinics, Hospitals
• Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Company Profiles: Boston Scientific Corporation, Medtronic plc, Cook Medical LLC, W. L. Gore & Associates, Inc., Taewoong Medical Co., Ltd, Merit Medical Systems, Inc., Novatech SA, Meril Life Sciences Pvt. Ltd, Stening SRL, BVM Medical Limited

Key Takeaways: Insights for Decision-Makers

• Lung stent technology is shifting toward bioresorbable and drug-eluting designs, reducing long-term complications and broadening clinical utility.
• Personalized stent solutions leveraging advanced materials and imaging are emerging to meet the needs of diverse patient anatomies and indications.
• Regulatory bodies have adapted pathways for innovative products, prompting manufacturers to enhance quality systems and post-market surveillance.
• Manufacturing supply chains are realigning due to market pressures and evolving regulations, with a growth in domestic production capabilities and regional supplier partnerships.
• Diversified procurement channels are optimizing device availability and cost-effectiveness for providers and health systems.
• Industry consolidation and partnerships with research centers are accelerating product launches and facilitating compliance in a dynamic policy landscape.

Tariff Impact: Navigating New U.S. Trade Measures

Recent U.S. tariffs on core materials such as nitinol, stainless steel, and innovative polymers have increased manufacturing costs and prompted strategic supply chain shifts for lung stent producers. Some companies have localized production and expanded regional supplier networks to manage these changes. Healthcare providers are adjusting inventory and procurement practices to maintain continuity and optimize expenditure under the new tariff environment. Risk mitigation and resilient sourcing strategies are becoming integral to market operations.

Methodology & Data Sources

This analysis is grounded in a multi-source approach, including systematic reviews of academic literature, regulatory documents, and proprietary databases. Primary interviews with clinical experts and industry stakeholders supplemented quantitative findings. Rigorous data triangulation, statistical adjustments for regional pricing and reimbursement, and frequent expert validation ensure the credibility of insights and forecasts.

Why This Report Matters

• Enables confident decision-making with detailed segmentation analysis and regulatory mapping across product types, patient groups, and regions.
• Highlights risk and opportunity areas driven by new market entrants, technology adoption, and policy changes—including U.S. tariff effects on supply and cost structure.
• Offers actionable intelligence for product development, strategic partnerships, and market entry in key geographies and emerging niches.

Conclusion

The lung stents market is undergoing significant transformation, shaped by innovation, regulatory adaptation, and regional market evolution. Senior leaders leveraging these insights can position their organizations to advance care outcomes and foster competitive strength amid ongoing change.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.